Claims for Patent: 5,597,815
✉ Email this page to a colleague
Summary for Patent: 5,597,815
| Title: | Prevention of hyperphosphatemia in kidney disorder patients |
| Abstract: | The 19-nor-vitamin D analogs, and particularly 19-nor-1.alpha.,25-dihydroxyvitamin D.sub.2, possess low calcemic and phosphatemic activity while also having the ability to suppress parathyroid hormone (PTH) production. The suppressive effect on PTH secretion of these 19-nor analogs without significant changes in serum calcium or serum phosphorus make them ideal tools for the treatment of secondary hyperparathyroidism in patients having kidney disorders. |
| Inventor(s): | Deluca; Hector F. (Deerfield, WI), Slatopolsky; Eduardo (St. Louis, MO) |
| Assignee: | Wisconsin Alumni Research Foundation (Madison, WI) |
| Application Number: | 08/502,288 |
| Patent Claims: |
1. A method of treating a patient having renal osteodystrophy while avoiding hyperphosphatemia comprising administering to said patient a vitamin D compound that has minimal effect on
blood serum phosphorus of said patient, said vitamin D compound selected from a 19-nor-vitamin D.sub.2 compound having the formula: ##STR5## where X.sup.1 and X.sup.2 each represent, independently, hydrogen or a hydroxy-protecting group; and where
R.sup.1 is selected from hydrogen, hydroxy, protected hydroxy, fluoro, trifluoromethyl, and C.sub.1-5 -- alkyl, which may be straight chain or branched and, optionally, bear a hydroxy or protected-hydroxy substituent; and where each of R.sup.2, R.sup.3,
and R.sup. 4, independently, is selected from hydrogen, fluoro, trifluoromethyl and C.sub.1-5 alkyl, which may be straight-chain or branched, and optionally, bear a hydroxy or protected-hydroxy substituent; and where R.sup.1 and R.sup.2, taken together
represent an oxo group, or an alkylidene group, .dbd.CR.sup.2 R.sup.3, or the group --(CH.sub.2).sub.p --, where p is an integer from 2 to 5; and where R.sup.3 and R.sup.4, taken together, present an oxo group, or a group --(CH.sub.2).sub.q --, where q
is an integer from 2 to 5; and where R.sup.5 represents hydrogen, hydroxy, protected hydroxy, or C.sub.1-5 alkyl.
2. The method of claim 1 wherein said vitamin D compound is administered together with a pharmaceutically accept, able excipient. 3. The method of claim 1 wherein said vitamin D compound is in a solid or liquid vehicle ingestible by and non-toxic to the patient. 4. The method of claim 1 where the said vitamin D compound is 1.alpha.,25-dihydroxy-19-nor-vitamin D.sub.2. 5. The method of claim 1 where the said vitamin D compound is 1.alpha.-hydroxy-19-nor-vitamin D.sub.2. 6. The method of claim 1 where the said vitamin D compound is 1.alpha.-hydroxy-19-nor-24-epi-vitamin D.sub.2. 7. The method of claim 1 where the said vitamin D compound is 1.alpha.,25-dihydroxy),-19-nor-24-epi-vitamin D.sub.2. 8. The method of claim 1 where the said vitamin D compound is administered orally. 9. The method of claim 1 where the said vitamin D compound is administered parenterally. 10. The method of claim 1 where the said vitamin D compound is administered topically. 11. The method of claim 1 where the said vitamin D compound is administered in an amount from 1 .mu.g to about 500 .mu.g per day to the patient. |
